Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis. (ORANGES)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03422159 |
|
Recruitment Status :
Recruiting
First Posted : February 5, 2018
Last Update Posted : June 14, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study has been created to compare the addition of intravenous (IV) vitamin C, thiamine, and hydrocortisone to the usual standard of care of sepsis and septic shock. Sepsis is a possibly life-threatening condition in which a patient may have organ dysfunction due to an infection. Septic shock is defined as low blood pressure and organ dysfunction that do not improve after administering IV fluids. Standard of care for sepsis and septic shock include early administration of IV antibiotics, IV fluids, and vasopressors if need be to provide oxygen to vital organs.
A large amount of experimental data has shown that vitamin C and corticosteroids decrease the release of inflammatory substances which may lead to organ failure seen in sepsis. Vitamin C and corticosteroids also improve blood flow to vital organs and increase the body's ability to respond well to vasopressor medications used in septic shock. Low blood levels of both thiamine and vitamin C are common in sepsis. The study will be placebo controlled, meaning one group will receive vitamin C, thiamine, and hydrocortisone, and the other will receive an inactive substance ("placebo"). The goal of the study is to compare the effects of receiving vitamin C, thiamine, and hydrocortisone (along with the standard sepsis care) versus placebo and standard sepsis care.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Sepsis, Severe Septic Shock | Drug: Ascorbic Acid Drug: Thiamine Drug: Hydrocortisone Drug: Sodium Chloride 0.9% | Phase 2 |
Show Detailed Description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 140 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This is a double-blind placebo controlled study. Only the dispensing pharmacist will be aware of the treatment allocation. Patients will be randomized to receive either vitamin C/hydrocortisone/thiamine or triple placebo using a random number table provided to the dispensing pharmacists. Each patient will be allocated a unique subject ID which will be linked to the randomization sequence. Only the dispensing pharmacists will have a record of the subject ID and randomization sequence. |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Masking Description: | Patients will be randomized to receive either vitamin C/hydrocortisone/thiamine or triple placebo using a random number table provided to the dispensing pharmacists. Each patient will be allocated a unique subject ID which will be linked to the randomization sequence. Only the dispensing pharmacists will have a record of the subject ID and randomization sequence. |
| Primary Purpose: | Treatment |
| Official Title: | Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis. |
| Actual Study Start Date : | February 5, 2018 |
| Estimated Primary Completion Date : | February 5, 2019 |
| Estimated Study Completion Date : | June 1, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment Arm
Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
|
Drug: Ascorbic Acid
Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Other Name: Vitamin C Drug: Thiamine Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days). Drug: Hydrocortisone Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Other Name: Solucortef |
|
Placebo Comparator: Placebo Arm
Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled "Vitamin C or Placebo". Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled "Thiamine 200mg or Placebo" and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior.
|
Drug: Sodium Chloride 0.9%
Placebo "Ascorbic Acid" 100mL IV piggyback every 6 hours, Placebo "Thiamine" 50mL IV piggyback every 12 hours, and Placebo "Hydrocortisone" IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Other Name: Placebo |
- Hospital Mortality [ Time Frame: Through study completion ]In-hospital mortality rate.
- 28-day mortality [ Time Frame: 28 days post-randomization ]28 day mortality rate
- Time to vasopressor independence (hours) [ Time Frame: Through study completion ]Defined as the time from starting the active treatment/placebo to discontinuation of all pressors.
- Procalcitonin (PCT) clearance [ Time Frame: 4 days post-randomization ]PCT at 96 hours minus initial PCT, divided by the initial PCT multiplied by 100.
- Change in Sequential Organ Failure Assessment (SOFA) score [ Time Frame: 4 days post-randomization ]Defined as the day 4 post-randomization SOFA score minus the initial SOFA score. SOFA score ranges from 0 (no organ dysfunction) to 24 (highest possible score / organ dysfunction).
- ICU Mortality [ Time Frame: Through study completion ]ICU mortality rate
- ICU Length of Stay [ Time Frame: Through study completion ]Time from admitting to ICU to discharge.
- ICU-Free Days [ Time Frame: 28 Days post-randomization ]Number of days alive and out of the ICU at day 28.
- Hospital Length of Stay [ Time Frame: Through study completion ]Time from admitting to discharge of hospital stay.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
i. Diagnosis of sepsis or septic shock within 12 hours of admission to the ICU ii. Informed consent as dictated by IRB and local practice. iii. Compliance with the 3 hour sepsis bundle
- 30ml/kg of intravenous crystalloid fluid (e.g.: sodium chloride 0.9%) for lactic acid >4 and/or systolic blood pressure <90mmHg / mean arterial pressure <65mmHg
- Lactic acid level drawn
- Broad spectrum antibiotics given after obtaining blood cultures
Exclusion Criteria:
i. Age < 18 years ii. Pregnant iii. DNR/DNI with limitations of care on admission iv. Patients with terminal end stage disease (i.e. stage IV cancer, end stage heart failure) that are unlikely to survive to hospital discharge v. Patients with a primary admitting diagnosis of an acute cerebral vascular event, acute coronary syndrome, active gastrointestinal bleeding, burn or trauma [64-66] vi. Requirement for immediate surgery [64-66] vii. Patients with HIV and a CD4 < 50 mm2 [64-66] viii. Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency.[39] ix. Patients with sepsis/septic shock transferred from another hospital x. Patients with features of sepsis/septic shock > 24 hours after admission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03422159
| Contact: Andrew V Vassallo, PharmD | 732-557-8000 ext 12929 | Andrew.Vassallo@rwjbh.org |
| United States, New Jersey | |
| Monmouth Medical Center, Southern Campus | Not yet recruiting |
| Lakewood, New Jersey, United States, 08701 | |
| Contact: Yasmine Elbaga, PharmD | |
| Community Medical Center | Recruiting |
| Toms River, New Jersey, United States, 08755 | |
| Contact: Andrew V Vassallo, PharmD 732-557-8000 ext 11992 Andrew.Vassallo@rwjbh.org | |
| Contact: Jose Iglesias, DO | |
Documents provided by Community Medical Center, Toms River, NJ:
Publications:
| Responsible Party: | Community Medical Center, Toms River, NJ |
| ClinicalTrials.gov Identifier: | NCT03422159 History of Changes |
| Other Study ID Numbers: |
17-004 |
| First Posted: | February 5, 2018 Key Record Dates |
| Last Update Posted: | June 14, 2018 |
| Last Verified: | June 2018 |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
| Product Manufactured in and Exported from the U.S.: | No | |
Additional relevant MeSH terms:
|
Sepsis Toxemia Shock, Septic Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes Shock Vitamins Ascorbic Acid Thiamine Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate |
Cortisol succinate Hydrocortisone Glucocorticoids Micronutrients Growth Substances Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Anti-Inflammatory Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Vitamin B Complex |